

---

# 5.30.005

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2024
<b>Subsection:</b>	Endocrine and Metabolic Drugs	<b>Original Policy Date:</b>	September 8, 2011
<b>Subject:</b>	Egrifita SV	<b>Page:</b>	1 of 4

---

**Last Review Date:** March 8, 2024

---

## Egrifita SV

### Description

#### Egrifita SV (tesamorelin)

---

#### Background

Egrifita SV is approved by the FDA for HIV-associated lipodystrophy which is defined as a condition in which excess fat develops in different areas of the body, especially around the liver, stomach and other abdominal organs commonly observed in HIV-infected patients. Egrifita SV is a growth hormone releasing factor (GRF) analog that acts on pituitary cells in the brain to stimulate the production and release of endogenous growth hormone (1).

Egrifita SV stimulates growth hormone production and increases serum IGF-1. Given that IGF-1 is a growth factor and the effect of prolonged elevations in IGF-1 levels on the development or progression of malignancies is unknown, any pre-existing malignancy should be inactive, and treatment should be completed prior to initiating therapy with Egrifita SV. IGF-1 levels should be monitored closely during Egrifita SV therapy. Careful consideration should be given to discontinuing Egrifita SV in patients with persistent elevations of IGF-1 levels, particularly if the efficacy response is not robust (1).

#### Regulatory Status

FDA-approved indication:

Egrifita SV is a growth hormone releasing factor (GRF) analog indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy (1).

Limitations of Use: (1)

# 5.30.005

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2024
<b>Subsection:</b>	Endocrine and Metabolic Drugs	<b>Original Policy Date:</b>	September 8, 2011
<b>Subject:</b>	Egriftra SV	<b>Page:</b>	2 of 4

---

- Long-term cardiovascular benefit and safety of Egriftra SV have not been studied
- Not indicated for weight loss management (weight neutral effect)
- There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking Egriftra SV

Egriftra SV is contraindicated in women who are pregnant, in patients with disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation or head trauma, in patients with known hypersensitivity to Egriftra SV and or mannitol, and in patients with active malignancies. Egriftra SV therapy should be discontinued if pregnancy occurs; therefore, a positive pregnancy test prohibits therapy (1).

Preexisting malignancy should be inactive, and its treatment complete prior to starting Egriftra SV therapy (1).

Egriftra SV treatment may result in glucose intolerance. An increased risk of developing diabetes with Egriftra SV relative to placebo was observed. Therefore, glucose status should be carefully evaluated prior to initiating Egriftra SV treatment. Patients must have their glucose status checked routinely (1).

---

## Related policies

### Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Egriftra SV may be considered **medically necessary** if the conditions indicated below are met.

Egriftra SV may be considered **investigational** for all other indications.

## Prior-Approval Requirements

**Age** 18 years old or older

### Diagnosis

Patient must have the following:

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2024
<b>Subsection:</b>	Endocrine and Metabolic Drugs	<b>Original Policy Date:</b>	September 8, 2011
<b>Subject:</b>	Egrifta SV	<b>Page:</b>	3 of 4

---

HIV-associated lipodystrophy with excess abdominal (visceral) fat

**AND ALL** of the following:

1. Concomitant antiretroviral therapy
2. No evidence of active malignancy
3. Women of child-bearing age must have a negative pregnancy test

---

## **Prior – Approval *Renewal* Requirements**

**Age** 18 years old or older

### **Diagnosis**

Patient must have the following:

HIV-associated lipodystrophy

**AND ALL** of the following:

1. Concomitant antiretroviral therapy
2. No evidence of active malignancy
3. Physician confirmation of glucose monitoring
4. Visceral adipose tissue (VAT) decrease as shown by a decrease in waist circumference or CT scan
5. Women of child-bearing age must have a negative pregnancy test

## **Policy Guidelines**

### **Pre - PA Allowance**

None

### **Prior - Approval Limits**

**Duration** 3 months

---

## **Prior – Approval *Renewal* Limits**

**Duration** 6 months

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2024
<b>Subsection:</b>	Endocrine and Metabolic Drugs	<b>Original Policy Date:</b>	September 8, 2011
<b>Subject:</b>	Egrifita SV	<b>Page:</b>	4 of 4

---

## Rationale

### Summary

Egrifita SV is approved for HIV-associated lipodystrophy in patients 18 years of age and older. It is contraindicated in women who are pregnant and preexisting malignancies. Treatment may result in glucose intolerance (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Egrifita SV while maintaining optimal therapeutic outcomes.

### References

1. Egrifita SV [package insert]. Montreal, Canada: Theratechnologies Inc.; October 2019.

## Policy History

Date	Action
December 2012	Annual editorial review and update
June 2014	Annual editorial review and update.
September 2015	Annual editorial review and reference update
September 2016	Annual editorial review and reference update Policy number change from 5.08.05 to 5.30.05
December 2017	Annual editorial review Addition of age requirement in renewal section
November 2018	Annual review and reference update
December 2019	Annual review and reference update
December 2020	Annual review and reference update
March 2021	Annual editorial review. Renamed policy Egrifita SV
March 2022	Annual review
March 2023	Annual review. Changed policy number to 5.30.005
June 2023	Annual review
March 2024	Annual review

## Keywords

---

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 8, 2024 and is effective on April 1, 2024.**